GC
TEVA icon

Guggenheim Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Guggenheim Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Sell
10,546
-69,241
-87% -$2.31M ﹤0.01% 1431
2026
Q1 		$2.4M Sell
79,787
-434
-0.5% -$14K 0.02% 644
2025
Q4 		$2.5M Sell
80,221
-3,595
-4% -$88.6K 0.02% 608
2025
Q3 		$1.69M Sell
83,816
-627
-0.7% -$11K 0.01% 727
2025
Q2 		$1.42M Sell
84,443
-3,041
-3% -$49.1K 0.01% 773
2025
Q1 		$1.34M Buy
87,484
+10,622
+14% +$190K 0.01% 772
2024
Q4 		$1.69M Sell
76,862
-446
-0.6% -$8.11K 0.01% 708
2024
Q3 		$1.39M Sell
77,308
-350
-0.5% -$6.13K 0.01% 960
2024
Q2 		$1.26M Buy
77,658
+44,415
+134% +$684K 0.01% 1001
2024
Q1 		$469K Buy
33,243
+7,630
+30% +$96.2K ﹤0.01% 1499
2023
Q4 		$267K Sell
25,613
-3,931
-13% -$36.7K ﹤0.01% 1718
2023
Q3 		$301K Sell
29,544
-12,049
-29% -$112K ﹤0.01% 1626
2023
Q2 		$313K Sell
41,593
-3,745
-8% -$30.4K ﹤0.01% 1647
2023
Q1 		$401K Buy
+45,338
New +$448K ﹤0.01% 1580
2021
Q4 		– Sell
-43,463
Closed -$424K – 2224
2021
Q3 		$424K Buy
43,463
+12,316
+40% +$115K ﹤0.01% 1815
2021
Q2 		$309K Buy
31,147
+5,327
+21% +$56.4K ﹤0.01% 2010
2021
Q1 		$298K Sell
25,820
-9,275
-26% -$106K ﹤0.01% 1955
2020
Q4 		$338K Buy
+35,095
New +$336K ﹤0.01% 1788
2019
Q4 		– Sell
-48,205
Closed -$332K – 2165
2019
Q3 		$332K Sell
48,205
-14,500
-23% -$111K ﹤0.01% 1805
2019
Q2 		$579K Buy
62,705
+11,633
+23% +$140K ﹤0.01% 1590
2019
Q1 		$801K Sell
51,072
-2,400
-4% -$42.3K 0.01% 1482
2018
Q4 		$824K Buy
53,472
+271
+0.5% +$5.56K 0.01% 1459
2018
Q3 		$1.15M Buy
53,201
+8,063
+18% +$187K 0.01% 1547
2018
Q2 		$1.1M Sell
45,138
-11,537
-20% -$235K 0.01% 1561
2018
Q1 		$969K Sell
56,675
-10,794
-16% -$211K ﹤0.01% 2088
2017
Q4 		$1.28M Sell
67,469
-7,514
-10% -$113K ﹤0.01% 1945
2017
Q3 		$1.32M Buy
74,983
+32,065
+75% +$721K ﹤0.01% 1926
2017
Q2 		$1.43M Buy
42,918
+1,347
+3% +$41.7K ﹤0.01% 1856
2017
Q1 		$1.33M Buy
41,571
+1,295
+3% +$44.2K ﹤0.01% 1934
2016
Q4 		$1.46M Buy
40,276
+446
+1% +$17.8K ﹤0.01% 1905
2016
Q3 		$1.83M Buy
39,830
+472
+1% +$24.6K 0.01% 1681
2016
Q2 		$1.98M Buy
39,358
+8,414
+27% +$448K 0.01% 1571
2016
Q1 		$1.66M Buy
30,944
+330
+1% +$19.4K 0.01% 1697
2015
Q4 		$2.01M Sell
30,614
-106,874
-78% -$6.6M 0.01% 1606
2015
Q3 		$7.76M Sell
137,488
-143,460
-51% -$9.3M 0.02% 852
2015
Q2 		$16.6M Sell
280,948
-87,707
-24% -$5.41M 0.04% 660
2015
Q1 		$23M Sell
368,655
-7,765
-2% -$451K 0.05% 607
2014
Q4 		$21.6M Sell
376,420
-13,131
-3% -$732K 0.05% 616
2014
Q3 		$20.9M Buy
389,551
+7,135
+2% +$378K 0.05% 630
2014
Q2 		$20.1M Buy
382,416
+65,037
+20% +$3.32M 0.05% 657
2014
Q1 		$16.8M Buy
317,379
+32,553
+11% +$1.5M 0.05% 690
2013
Q4 		$11.4M Sell
284,826
-4,130
-1% -$163K 0.03% 784
2013
Q3 		$10.9M Buy
288,956
+13,841
+5% +$540K 0.04% 803
2013
Q2 		$10.8M Buy
+275,115
New +$10.7M 0.05% 738

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Guggenheim Capital's TEVA Position: Q2 2026 in Review

Guggenheim Capital reduced its Teva Pharmaceuticals (TEVA) stake by 87% in Q2 2026, selling an estimated $2.31M and leaving 10,546 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #1431.

Guggenheim Capital first reported a position in TEVA in Q2 2013 and has held it in 44 quarters since. The position peaked at $23M in Q1 2015. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Guggenheim Capital held 10,546 shares of Teva Pharmaceuticals worth $357K as of Q2 2026.
  • Guggenheim Capital sold 69,241 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.31M.
  • Teva Pharmaceuticals made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1431 holding.
  • Guggenheim Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Guggenheim Capital's Teva Pharmaceuticals position peaked at $23M in Q1 2015.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.